Aldeyra braces for po­ten­tial dry eye dis­ease re­jec­tion af­ter FDA says more da­ta are nec­es­sary

Aldeyra Ther­a­peu­tics is brac­ing for a po­ten­tial re­jec­tion of re­prox­alap months af­ter bold­ly tout­ing its ap­pli­ca­tion as “the most com­pre­hen­sive NDA pack­age ever sub­mit­ted for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER